Every 8-K that Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CYCCP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYCCP filings page.
Bio Green Med Solution, Inc. entered into a Securities Purchase Agreement with foreign accredited investors to sell 1,103,338 shares of common stock at $0.72 per share, raising aggregate gross proceeds of $794,403. The closing occurred on June 10, 2026, and the company plans to use the cash for general corporate and operating purposes.
At the same time, the company signed a Registration Rights Agreement requiring it to file and maintain an effective resale registration statement so investors can later resell these shares under the Securities Act or Rule 144. The shares were issued without registration under Regulation S to non‑U.S. persons.
Bio Green Med Solution, Inc. entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. in an all‑stock share exchange. Future NRG will become a wholly owned subsidiary, while its selling shareholders are expected to own more than 99% of the combined company, leaving pre‑transaction Bio Green Med holders with less than 1%.
The deal aims to build a next‑generation environmental platform by combining Bio Green Med’s fire safety equipment business with Future NRG’s medical waste‑to‑energy operations in Malaysia. Closing requires shareholder approvals, Nasdaq listing approval for new shares, effectiveness of a Form S‑4 registration statement and other customary conditions, and may be terminated if not completed by December 31, 2026.
Bio Green Med Solution, Inc. reported first quarter 2026 results showing its transition into fire safety operations gaining traction but still producing a small loss. Product revenue from fire safety equipment reached $0.8 million for the three months ended March 31, 2026, with cost of sales of $0.6 million, reflecting an early revenue base in the new business.
General and administrative expenses fell sharply to $0.4 million from $4.2 million a year earlier, mainly as one-time change-of-control costs rolled off and management focused on tighter cost control. The company recorded a net loss of $0.2 million, similar to the prior-year loss from continuing and discontinued operations combined.
Cash and cash equivalents were $3.3 million as of March 31, 2026, and Bio Green Med estimates these resources will fund planned expenditures into the fourth quarter of 2026. During the quarter, its 6% Convertible Exchangeable Preferred Stock was delisted from Nasdaq, although the common stock remains listed, and holders of the preferred received a $0.15 per-share quarterly cash dividend paid on May 1, 2026.
Bio Green Med Solution, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on May 1, 2026 to preferred stockholders of record at the close of business on April 23, 2026.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., filed an amended current report to correct a presentation detail only. This Amendment No. 1 to the previously filed report updates the cover page to display the company’s correct new logo that aligns with its updated name and ticker symbol, as previously announced. The company states that no other changes have been made to the original report.
Cyclacel Pharmaceuticals, Inc. reported that shareholders approved all proposals at a special meeting held on September 4, 2025. Investors backed the issuance of Cyclacel common stock to Fitters Parent under an Exchange Agreement, with 1,095,988 votes in favor and a reported 58.8% support level.
Shareholders also approved the potential issuance of more than 20% of the company’s outstanding common stock in connection with a transaction to comply with Nasdaq Listing Rule 5635(a), with similar voting support. In addition, they approved amending the certificate of incorporation to change the company’s name to Bio Green Med Solution, Inc., permit stockholder actions by written consent, ratify prior written-consent actions, and opt out of the business combination provisions of Section 203 of the Delaware General Corporation Law.
Cyclacel Pharmaceuticals, Inc. entered into a Warrant Exchange Agreement with certain accredited investors on September 4, 2025. The company agreed to exchange existing Series C common stock purchase warrants, which were exercisable for an aggregate of 559,395 shares of common stock, for an equal aggregate of 559,395 new shares of common stock issued directly to the holders.
The exchanged warrants were originally issued under a securities purchase agreement dated June 20, 2025. The new shares will be issued without registration under the Securities Act of 1933 in reliance on the Section 3(a)(9) exemption, meaning they are part of a private, unregistered exchange with existing security holders.
Cyclacel Pharmaceuticals, Inc. reported that on September 1, 2025 it entered into amended and restated Series A, B and C common stock purchase warrants. These amendments remove a prior Ownership Limitation that had restricted exercises so holders could not own or vote more than the lower of a Nasdaq-based cap and 4.99% of the company’s common stock before stockholder approval. Board and majority stockholder approval for removing this limit was obtained as described in a Schedule 14C effective July 28, 2025.
The amended Series A warrants allow each holder to purchase 218,000 common shares at $7.65 per share, Series B warrants allow 218,000 shares at $9.00 per share, and Series C warrants allow 218,000 shares at $10.20 per share. Each series now has an expiration date five years from its issuance.
Cyclacel Pharmaceuticals, Inc. changed its independent auditor and disclosed serious funding concerns. On August 22, 2025, the board’s Audit Committee dismissed Bush & Associates CPA LLP and approved the appointment of SFAI Malaysia PLT as the new independent registered public accounting firm for the year ending December 31, 2025.
From November 5, 2024 to August 22, 2025, the company reports no accounting disagreements with Bush, but Bush advised that Cyclacel does not have sufficient funds to complete development and commercialization and had a limited cash balance as of December 31, 2024. Bush indicated this situation raises substantial doubt about Cyclacel’s ability to continue as a going concern.
Cyclacel Pharmaceuticals, Inc. furnished a current report to share that it issued a press release detailing its second quarter 2025 results. The company attached this press release as Exhibit 99.1 and designated the information under both results of operations and Regulation FD disclosure, indicating it is being provided for informational purposes rather than as a filed financial statement.
Cyclacel Pharmaceuticals disclosed that it is presenting audited consolidated financial statements for the quarter ended March 31, 2025 to satisfy the eligibility requirements of a registration statement on Form S-3. The filing indicates the company is providing its audited quarter-end financials and related notes so it meets the stated Form S-3 condition for shelf or registered offerings.
The report lists two exhibits: Exhibit 99.1 (the audited financial statements for the quarter) and Exhibit 104 (the cover page interactive XBRL data). The filing itself does not include income statement, balance sheet, or management discussion figures within the report text provided.
Cyclacel Pharmaceuticals, Inc. (CYCC/CYCCP) filed an 8-K announcing a private placement of Series F Convertible Preferred Stock and accompanying warrants that closed on 20 June 2025. The company entered into a Securities Purchase Agreement with accredited investors for 3 million shares of Series F Preferred Stock at $1.00 per share, generating $3.0 million in gross proceeds to be used for general corporate and operating purposes.
Dilution mechanics: Each preferred share converts into 3.27 common shares, implying an effective conversion price of roughly $0.31 per common share. Full conversion would create up to ≈9.81 million new common shares, subject to a 4.99 % ownership cap per investor until stockholder approval is obtained. In addition, investors received 29.43 million five-year warrants split into three tranches with exercise prices of $0.51 (Series A), $0.60 (Series B) and $0.68 (Series C) per share. The warrants and preferred shares were issued under Regulation S and are therefore unregistered.
Governance & rights: The Series F Preferred votes with common stock on an as-converted basis (subject to the ownership cap), participates in common dividends, and carries a $1.00 per-share liquidation preference pari passu with other preferred stock. The company has committed to seek stockholder approval for the full issuance of common shares underlying the preferred and the warrants to comply with Nasdaq rules.
Key implications: The financing provides near-term liquidity but introduces the potential for significant future share dilution—up to ~39.2 million additional common shares if all instruments are exercised/converted. Investor approval risk, dilution magnitude, and relatively low effective conversion price are material considerations for existing shareholders.